Skip to content
RushPR News – Lifestyle
Author:
MeiraGTx
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
September 23, 2026
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
August 13, 2026
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
July 7, 2026
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
May 14, 2026
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
April 16, 2026
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
April 16, 2026
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
April 16, 2026
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
April 14, 2026
1
2
Next Page
→